Richard A Larson MD

PubMed

• Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.
  Joshua F Zeidner, David A Sallman, Christian Récher, Naval G Daver, Anskar Yh Leung
  Blood. 2025-02-26
• Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study.
  Marlise R Luskin, Jun Yin, Gerard Lozanski, Emily Curran, Gregory Malnassy
  Cancer. 2025-02-15
• Randomized Phase II Study to Assess the Role of Single-Agent Nivolumab to Maintain Remission in Acute Myeloid Leukemia.
  Athalia Rachel Pyzer, Laura W Dillon, Elad Sharon, Theodore G Karrison, Yuanyuan Zha
  Blood Advances. 2025-02-10

Abstracts/Posters

• Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors
  Richard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ibrutinib and Venetoclax Target Distinct Subpopulation of CLL Cells: Rationale for Drug Combination and Implication of Minimal Residual Disease Eradication
  Richard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS
  Richard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis
  Richard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd
  Richard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia
  Richard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral TrialCl...
  Richard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young ...
  Richard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• ABL Tyrosine Kinase Inhibitors (TKIs) Are Associated with Increased Rho-Associated Kinase (ROCK) Activity That May Contribute to Vascular Toxicity in Patients with Chr... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Rando... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete R... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• 2012 Highlights of ASH in North America (Las Vegas, NV) 
  American Society of Hematology (ASH), Las Vegas, Nevada - 1/27/2012
• 2012 Highlights of ASH in North America (Austin, TX) 
  American Society of Hematology (ASH), Austin, Texas - 1/20/2012
• Join now to see all